Heart disease is the leading cause of death in women in the US and accounts for more deaths each year than all other causes combined. In women of racial or ethnic minority the rates of death are even higher. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the risk of heart disease in women and empower them to be advocates for women’s cardiovascular health.

This educational symposium will define risk factors for cardiovascular disease in women and how they differ from men, the impact of cardiovascular disease in women worldwide, and gender-specific treatments. Discussions will include pathophysiology of pregnancy related complications, the risks and benefits of hormone therapy, the benefits of biventricular therapy in women and heart failure management, and advances in management of dyslipidemia, atrial fibrillation and coronary microvascular dysfunction. State of the art therapies for structural heart disease, with an emphasis on outcomes in women, will be discussed.

The objective of this symposium is to educate healthcare providers on gender-appropriate approaches in prevention, diagnosis and treatment of women with a broad range of cardiovascular diseases.

TARGET AUDIENCE
This program has been designed to provide primary care physicians, internists, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists and other healthcare providers with the necessary information to increase knowledge and awareness of cardiovascular disease in women with the goal of improving patient care.

OBJECTIVES
1. Understand the impact of cardiovascular disease in women, including current incidence and prevalence
2. Review the risks, presentation and current guidelines for treatment of CAD in women
3. Explore the diagnosis and management of chest pain in women without obstructive CAD
4. Discuss preconception counseling for women with various existing cardiovascular disorders during pregnancy
5. Understand the management of women with common cardiovascular disorders
6. Review current management guidelines for hyperlipidemia and discuss newer, non-statin therapies
7. Discuss updated off-label and exercise guidelines
8. Understand the diagnosis and management of dysautonomia
9. Discuss updates on medical and device therapies for heart failure in women
10. Review pharmacologic and nonpharmacologic therapies for prevention of thromboembolic complications in atrial fibrillation
11. Review updated indications and compare the current outcomes in transcatheter vs surgical aortic valve replacement in women
FACULTY

Christina Economides, MD*
C flavorful Women’s Cardiovascular Health Program
Director, Cardiac Rehabilitation Program
Co-director, Transradial Cardiac Catheterization Program
Director, Barbra Streisand Women’s Heart Center
Cedars-Sinai Heart Institute
Los Angeles, CA

Emily H. Caldwell, NP*
Dysautonomia Clinic - Supervising
Los Angeles Cardiology Associates
Los Angeles, CA

Ronald Victor, MD, FACC
Medical Director of Cardiology,
Los Angeles Cardiology Associates
Lead Nurse Practitioner
ACNP, AACC
UCLA School of Medicine
Cedars-Sinai Heart Institute
Los Angeles, CA

Priya Pilluha, MD, FACC
Assistant Professor of Medicine
Los Angeles Cardiology Associates
Good Samaritan Hospital
Los Angeles, CA

Janet Wei, MD, FACC
Co-Director, Women’s Cardiac Research Laboratory
Department of Cardiovascular Medicine
University of Utah School of Medicine
Salt Lake City, UT

Andrew Zadeh, MD, FACC, FSCAI
Los Angeles Cardiology Associates
Los Angeles, CA

Katrine Zhiroff, MD, FACC, FSCAI
Nurse Practitioner
Transradial Cardiac Catheterization Program
Good Samaritan Hospital
Los Angeles, CA

Marge B. Minassian, PhD
FAAIA, AACC
Associate Professor
Clinical Cardiology
Clinical Specialist
Barbra Streisand Women’s Heart Center
Cedars-Sinai Heart Institute
Los Angeles, CA

PROGRAM - Saturday, February 4

6:45 - 7:00 AM
Breakfast - Product Theatre (Non-CME)

7:00 - 7:45 AM
Putting Guidelines into Practice: New Recommendations for Optimal Treatment of Heart Failure with Reduced Ejection Fraction

Supported by Novartis Pharmaceuticals Corporation

8:00 - 8:30 AM
Cardiovascular Disease in Women: Scope of the Problem - 2017 Update
Christina Economides, MD

8:30 - 9:35 AM
Chest Pain in Women with No Obstructive Coronary Artery Disease: Diagnosis and Management
Lauri Weid, MD, FACC

9:35 - 10:00 AM
Look Before You Leap: Preconception Counseling for Women with Cardiovascular Disease
Priya Pilluha, MD

10:00 - 10:30 AM
Management of Common Cardiovascular Issues During Pregnancy
Priya Pilluha, MD

10:30 - 10:55 AM
Hyperension Management—To SPRINT or Not to SPRINT
Ronald Victor, MD

10:55 - 11:20 AM
A Pragmatic Approach to Non-Statin Therapies
Margot B. Minassian, PhD, FAHA

11:20 - 11:55 AM
Update on Lifestyle, Diet and Exercise Guidelines for Cardiovascular Disease. Prevention and Secondary Risk Reduction
Janet Wei, MD

11:55 - 12:05 PM
Speakers’ Panel: Question and Answer
Dr. Baldani, Dr. Wei, Dr. Zhiroff and Dr. Wei

12:05 - 12:15 PM
Working Lunch-Interventional Case Presentations

12:15 - 1:45 PM
Keynote Lecture
Understanding the Spectrum of Dysautonomia: Practical Approach to Diagnosis
Dr. Caldwell

1:45 - 2:05 PM
Treatment and Long-term Management of the Dysautonomic Patient
Emily Caldwell, ACNP

2:05 - 2:30 PM
Consecutive Heart Failure 2017 Update in Management
Katrine Zhiroff, MD, FACC, FSCAI

2:30 - 2:55 PM
Hematology: Cardiac Rosaryochromatosis Therapy in Women, Andrew Zadeh, MD, FACC, FSCAI

2:55 - 3:05 PM
Break

3:05 - 3:30 PM
The Evolving Landscape for Anticoagulation in Atrial Fibrillation: Selection of the Right Drug, Reversal Agents and Gender Differences
Avin Bhandari, MD, FACC, FSCAI

3:30 - 3:55 PM
Nonpharmacologic Therapy to Prevent Embolization in Patients with Atrial Fibrillation: Considerations in Women
Katherine Zhiroff, MD, FACC, FSCAI

3:55 - 4:20 PM
Transcateter AVR vs Surgical AVR: Update on Indications and Outcomes in Women
Avin Bhandari, MD, FACC, FSCAI

4:20 - 4:35 PM
Speakers’ Panel: Question and Answer
Adjourn

REGISTRATION FORM

2ND ANNUAL SYMPOSIUM
CONTEMPORARY MANAGEMENT OF CARDIOVASCULAR DISEASE IN WOMEN
FEBRUARY 4, 2017

Register Online at: WomensCVDLA.com

First Name __________________________________________
Last Name __________________________________________
Title ________________________________________________
Office Address ________________________________________
City _________________________________________________
State _________________________________________________
Zip __________________________ Phone ____________________
Fax _________________________________________________
Email ________________________________________________
Professionally Special Needs for Disabled

REGISTRATION FEES

ON OR BEFORE JANUARY 20, 2017 ON OR AFTER JANUARY 21, 2017
Physician Registration $100 $130
Nurse / Allied Health $75 $105
Physician in Training $75 $105

REGISTRATION FORM

Make payable to:
WomensCVDLA.com

Name ________________________________________________
Affiliation ____________________________________________
Address ______________________________________________
City _________________________________________________
State _________________________________________________
Zip _________________________________________________
Phone ________________________________________________
Fax _________________________________________________
Email ________________________________________________

8:30 AM

9:00 AM

9:30 AM

10:00 AM

10:30 AM

11:00 AM

11:30 AM

12:00 PM

12:30 PM

1:00 PM

1:30 PM

2:00 PM

2:30 PM

3:00 PM

3:30 PM

4:00 PM

4:30 PM

11:55-12:05
12:05-12:15
12:15-1:45
1:45-2:05
2:05-2:30
2:30-2:55
2:55-3:05
3:05-3:30
3:30-3:55
3:55-4:20
4:20-4:35

ACCREDITATION
This Live activity, 2nd Annual Contemporary Management of Cardiovascular Disease in Women, with a beginning date of February 4, 2017 has been reviewed and approved as equivalent to 8.75 CME credit hours by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award.

AANPCP: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AAPA CME credit.

ANCC, According to the ANCC, the continuing education hours allowed by the AAP should meet the ANCC-accredited CNE criteria.

AAPA: The American Academy of Physician Assistants accepts AAPA CME credit for AAPA Category 1 CME credit.

REGISTRATION FEES

ON OR BEFORE JANUARY 20, 2017 ON OR AFTER JANUARY 21, 2017
Physician Registration $100 $130
Nurse / Allied Health $75 $105
Physician in Training $75 $105

CANCELLATION POLICY
If your registration must be cancelled and a refund of your fee is desired, your fee, less $25 for administrative costs, will be refunded upon receipt of a written request that includes your signature. No refunds will be made after January 6, 2017. Please allow up to 6 weeks for a refund.

FURTHER INFORMATION
Complete Conference Information Phone: 619-299-6673
Fax: 619-299-6673
Email: info@ccmmeetings.com

CHECK OR MONEY ORDER PAYMENT (in US Dollars) Send check or money order payable to:
Good Samaritan Hospital
Complete Conference Management
3320 Third Avenue, Suite C
San Diego, CA 92103
Fax: 619-299-6673